// App-Quantinova.ai

4527 : Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.

Researchers

Presenter

  • Srikala S. Sridhar

Principal Investigators

  • Thomas Powles

  • Yohann Loriot

  • Miguel A. Climent Durn

  • Shilpa Gupta

  • Norihiko Tsuchiya

  • Aristotelis Bamias

  • Andrea Ardizzoni

  • Anders Ulln

  • Bo Huang

  • Nuno Matos Costa

  • Robert J Laliberte

  • Alessandra Di Pietro

  • Cora N. Sternberg

  • Petros Grivas

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomews Hospital, London, United Kingdom

  • Gustave Roussy, Universite Paris-Saclay, Villejuif, France

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH

  • Department of Neurosurgery, Yamagata University Faculty of Medicine, Yamagata, Japan

  • Laikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

  • Azienda Ospedaliera-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

  • Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Solna, Sweden

  • Pfizer, Groton, CT

  • Pfizer, Porto Salvo, Portugal

  • Pfizer Inc., Cambridge, MA

  • Pfizer Inc, Milan, Italy

  • Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.

  • University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA

Locations

  • Canada

  • United Kingdom

  • France

  • Spain

  • United States

  • Japan

  • Greece

  • Italy

  • Sweden

  • Portugal

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Tissue factor pathway inhibitor

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • 1L platinum

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02603432

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved